A Phase IIb/III, Double-Blind, Placebo-Controlled, Randomized Study Investigating the Safety, Tolerability and Efficacy of Flupirtine as Adjunct to Opioids When Administered to Cancer Subjects Who Are Experiencing Pain With Neuropathic Features

Trial Profile

A Phase IIb/III, Double-Blind, Placebo-Controlled, Randomized Study Investigating the Safety, Tolerability and Efficacy of Flupirtine as Adjunct to Opioids When Administered to Cancer Subjects Who Are Experiencing Pain With Neuropathic Features

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 May 2012

At a glance

  • Drugs Flupirtine (Primary)
  • Indications Cancer pain; Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Relevare Pharmaceuticals
  • Most Recent Events

    • 06 May 2012 New source identified and integrated (European Clinical Trials Database).
    • 06 May 2012 Status changed from planning to recruiting, according to the European Clinical Trials Database.
    • 28 May 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top